Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos said that its service division, BioFocus DPI, has entered into a new drug discovery collaboration with AstraZeneca, worth E680,000 to the Belgian biotech company.
Subscribe to our email newsletter
This announcement marks the third collaboration between AstraZeneca and BioFocus DPI. In August 2006, Galapagos announced BioFocus DPI’s first drug discovery collaboration with AstraZeneca. Under a second program initiated in April 2007, BioFocus DPI is performing chemistry and supporting biology and ADME services for an AstraZeneca hit-to-lead program.
While these collaborations focused on AstraZeneca’s European-based R&D, the agreement announced today expands BioFocus DPI’s drug discovery services to AstraZeneca’s US-based R&D.
“We now have a global relationship with AstraZeneca, working with several sites based in Europe and the US,” said Galapagos’ CEO, Onno van de Stolpe. “This type of expansion fits very well with our strategy for growth of the BioFocus DPI service division.”